Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction
- PMID: 34154628
- PMCID: PMC8215732
- DOI: 10.1186/s13019-021-01525-8
Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction
Erratum in
-
Correction to: Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction.J Cardiothorac Surg. 2021 Sep 3;16(1):247. doi: 10.1186/s13019-021-01629-1. J Cardiothorac Surg. 2021. PMID: 34474673 Free PMC article. No abstract available.
Abstract
Background: Drug-coated balloon (DCB) is a new technology that has emerged in recent years and has been proven to be effective and safe in the treatment of in-stent restenosis. The purpose of this article is to observe the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction.
Method: We selected 80 patients admitted to the hospital for STEMI from January 2018 to December 2019. The subjects were randomly divided into a Yinyi (Liaoning) Biotech Bingo Drug Coated Balloon treatment group (balloon group, n = 38) and a drug-eluting stent (DES) treatment group (stent group, n = 42). Patients were followed up to understand the incidence of major adverse cardiovascular events (MACE) at 1 month, 6 months and 1 year after surgery. Coronary angiography was rechecked 1 year after surgery to understand the late lumen loss (LLL) in the two groups.
Result: During the one-year follow-up, the LLL of the target lesion in the balloon group was -0.12±0.46 mm, while the target lesion in the stent group was 0.14±0.37 mm ( P <0.05). Within 1 year, the incidence of MACE in the balloon group was 11%, while the incidence of MACE in the stent group was 12%. There was no significant difference between the two groups.
In conclusion: When PCI is used for STEMI, only DCB therapy is safe and effective, and has shown good clinical effects during a one-year follow-up period.
Keywords: Acute ST-segment elevation myocardial infarction; Drug-coated balloon; Late lumen loss.
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction: The REVELATION Randomized Trial.JACC Cardiovasc Interv. 2019 Sep 9;12(17):1691-1699. doi: 10.1016/j.jcin.2019.04.016. Epub 2019 May 21. JACC Cardiovasc Interv. 2019. PMID: 31126887 Clinical Trial.
-
Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial.JACC Cardiovasc Interv. 2017 Jul 10;10(13):1332-1340. doi: 10.1016/j.jcin.2017.04.024. JACC Cardiovasc Interv. 2017. PMID: 28683939 Clinical Trial.
-
Efficacy of Drug-Eluting Balloons for Patients With In-Stent Restenosis: A Meta-Analysis of 8 Randomized Controlled Trials.Angiology. 2016 Aug;67(7):612-21. doi: 10.1177/0003319715611826. Epub 2015 Oct 18. Angiology. 2016. PMID: 26483569 Review.
-
REVascularization with paclitaxEL-coated balloon angioplasty versus drug-eluting stenting in acute myocardial infarcTION-A randomized controlled trial: Rationale and design of the REVELATION trial.Catheter Cardiovasc Interv. 2016 Jun;87(7):1213-21. doi: 10.1002/ccd.26241. Epub 2015 Sep 15. Catheter Cardiovasc Interv. 2016. PMID: 26370515 Clinical Trial.
-
Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation.Heart Vessels. 2016 Sep;31(9):1405-11. doi: 10.1007/s00380-015-0741-6. Epub 2015 Sep 4. Heart Vessels. 2016. PMID: 26337620
Cited by
-
Paclitaxel-eluting stents versus paclitaxel-coated balloons in coronary artery disease: a meta-analysis of randomized controlled trials.Glob Cardiol Sci Pract. 2024 Mar 3;2024(2):e202412. doi: 10.21542/gcsp.2024.12. eCollection 2024 Mar 3. Glob Cardiol Sci Pract. 2024. PMID: 38746063 Free PMC article. Review.
-
Drug-Coated Balloon in Acute Coronary Syndromes: Ready for the Prime Time?Curr Cardiol Rep. 2024 May;26(5):359-372. doi: 10.1007/s11886-024-02037-2. Epub 2024 Apr 15. Curr Cardiol Rep. 2024. PMID: 38619711 Review.
-
Cardiovascular Outcomes after Paclitaxel-Coated Balloon Angioplasty versus Drug-Eluting Stent Placement for Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.J Clin Med. 2024 Mar 4;13(5):1481. doi: 10.3390/jcm13051481. J Clin Med. 2024. PMID: 38592314 Free PMC article. Review.
-
Efficacy and safety of drug-coated balloon for de novo lesions of large coronary arteries: Systematic review and meta-analysis of randomized controlled trials.Heliyon. 2024 Jan 30;10(3):e25264. doi: 10.1016/j.heliyon.2024.e25264. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38333846 Free PMC article.
-
Comparison of Efficacy and Safety Between Drug-Coated Balloons Versus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions in Large Vessels: A Study-Level Meta-Analysis of Randomized Control Trials.Cardiovasc Drugs Ther. 2023 Nov 24. doi: 10.1007/s10557-023-07526-0. Online ahead of print. Cardiovasc Drugs Ther. 2023. PMID: 37999833
References
-
- Stone GW, Witzenbichiler B, Guagliumiu G, Peruga JZ, Brodie BR, Dudek D, etc. In acute myocardial infarction (HORIZONS-AMI) Heparinplus glycoprotein IIb / herIIIa inhibitor and bivalirudin monotherapy, inhibitor and bivalirudin monotherapy, and paclitaxel-eluting stent and bar mental stent comparison: the final 3 years from A multicenter, randomized controlled trial. Lancet. 2011;377:2193-204. - PubMed
-
- Luca GD, Suryapranata H, Stone GW, Antoniucci D, Biondi-Zoccai G, Kastrati A, etc. Coronary stenting and balloon angioplasty for acute myocardial infarction: Meta regression analysis of a randomized trial[J]. Int J glycol. 2008; 126(1):37-44. 10.1016/j.ijcard.2007.03.112. - PubMed
-
- Wang HR, Zhang CP, Wang Z, Zhang M, Zhao L. Clinical application and research status of drug-coated balloon in percutaneous coronary intervention. Chinese Medical Journal. 2019;10:1583-6.
-
- Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, etc. 2018 ESC / EACTS Myocardial Revascularization Guidelines. Eur Heart J. 2019;40(2):87–165. 10.1093/eurheartj/ehy394 . - PubMed
-
- Holmvang L, Kelbk H, Kaltto A, Thuesen L, Lassen JF, Clemmensen P, etc. Long-term results of ST-segmengt elevated myocardial infarction after the patient’s drug-eluting and bar psychological stent implantation: 5-year follow-up from random intermittent injection of CA TI (drug elution and distal protection for acute myocardial infarction) to titanium aluminum alloy. JACC Cardiovascular Intervention 2013;6960:548–53.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous